Glucose Variability Assessed with Continuous Glucose Monitoring: Reliability, Reference Values, and Correlations with Established Glycemic Indices-The Maastricht Study

被引:31
作者
Foreman, Yuri D. [1 ,2 ]
Brouwers, Martijn C. G. J. [2 ,3 ]
van der Kallen, Carla J. H. [1 ,2 ]
Pagen, Demi M. E. [1 ,2 ]
van Greevenbroek, Marleen M. J. [1 ,2 ]
Henry, Ronald M. A. [1 ,2 ,4 ]
Koster, Annemarie [5 ,6 ]
Wesselius, Anke [7 ]
Schaper, Nicolaas C. [2 ,3 ,5 ]
Stehouwer, Coen D. A. [1 ,2 ]
机构
[1] Maastricht Univ, Dept Internal Med, Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands
[3] Maastricht Univ, Dept Internal Med, Div Endocrinol & Metab Dis, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Heart & Vasc Ctr, Med Ctr, Maastricht, Netherlands
[5] Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, Maastricht, Netherlands
[6] Maastricht Univ, Dept Social Med, Maastricht, Netherlands
[7] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Complex Genet & Epidemiol, Maastricht, Netherlands
关键词
Continuous glucose monitoring; Epidemiology; Glucose variability; Oral glucose tolerance test; Reference values; Reliability; Type 2 diabetes mellitus; RANGES;
D O I
10.1089/dia.2019.0385
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Glucose variability (GV) measured by continuous glucose monitoring (CGM) has become an accepted marker of glycemic control. Nevertheless, several methodological aspects of GV assessment require further study. We, therefore, investigated the minimum number of days needed to reliably measure GV, assessed GV reference values, and studied the correlation of GV with established glycemic indices (i.e., HbA(1c), seven-point oral glucose tolerance test [OGTT]-derived indices). Methods: We used cross-sectional data from The Maastricht Study, an observational population-based cohort enriched with type 2 diabetes. Participants with more than 48 h of CGM (iPro2; Medtronic) were included for analysis (n = 851; age: 60 +/- 9years; 49% women; 23% type 2 diabetes). We used mean sensor glucose (MSG), standard deviation (SD), and coefficient of variation (CV) as CGM-derived indices (the latter two for GV quantification). We calculated reliability using the Spearman-Brown prophecy formula, established reference values by calculating 2.5th-97.5th percentiles, and studied correlations using Spearman's rho. Results: Sufficient reliability (R > 0.80) was achieved with two (MSG and SD), or three monitoring days (CV). The reference ranges, assessed in individuals with normal glucose metabolism (n = 470), were 90.5-120.6 mg/dL (MSG), 7.9-24.8 mg/dL (SD), and 7.74%-22.45% (CV). For MSG, the strongest correlation was found with fasting plasma glucose (rho = 0.65 [0.61; 0.69]); for SD, with the 1-h OGTT value (rho = 0.61 [0.56; 0.65]); and for CV, with both the incremental glucose peak (IGP) during the OGTT (rho = 0.50 [0.45; 0.55]) and the 1-h OGTT value (rho = 0.50 [0.45; 0.55]). Conclusions: The reliability findings and reference values are relevant for studies that aim to investigate CGM-measured GV. One-hour OGTT and IGP values can be used as GV indices when CGM is unavailable.
引用
收藏
页码:395 / 403
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation
[2]   Lessons learned from the 1-hour post-load glucose level during OGTT: Current screening recommendations for dysglycaemia should be revised [J].
Bergman, Michael ;
Jagannathan, Ram ;
Buysschaert, Martin ;
Pareek, Manan ;
Olsen, Michael H. ;
Nilsson, Peter M. ;
Medina, Jose Luis ;
Roth, Jesse ;
Chetrit, Angela ;
Groop, Leif ;
Dankner, Rachel .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34 (05)
[3]   Correlation in restricted ranges of data [J].
Bland, J. Martin ;
Altman, Douglas G. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 342 :d556
[4]   Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes [J].
Bode, BW ;
Schwartz, S ;
Stubbs, HA ;
Block, JE .
DIABETES CARE, 2005, 28 (10) :2361-2366
[5]   Glycemic variability:: A hemoglobin A1c-independent risk factor for diabetic complications [J].
Brownlee, M ;
Hirsch, IB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1707-1708
[6]   Glycemic Targets: Standards of Medical Care in Diabetes-2019 [J].
Cefalu, William T. ;
Berg, Erika Gebel ;
Saraco, Mindy ;
Petersen, Matthew P. ;
Uelmen, Sacha ;
Robinson, Shamera .
DIABETES CARE, 2019, 42 :S61-S70
[7]   Assessment of glucose variability in subjects with prediabetes [J].
Chakaroua, Nevena ;
Dimova, Rumyana ;
Grozeva, Greta ;
Tankoua, Tsvetalina .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 151 :56-64
[8]   International Consensus on Use of Continuous Glucose Monitoring [J].
Danne, Thomas ;
Nimri, Revital ;
Battelino, Tadej ;
Bergenstal, Richard M. ;
Close, Kelly L. ;
DeVries, J. Hans ;
Garg, Satish ;
Heinemann, Lutz ;
Hirsch, Irl ;
Amiel, Stephanie A. ;
Beck, Roy ;
Bosi, Emanuele ;
Buckingham, Bruce ;
Cobelli, Claudio ;
Dassau, Eyal ;
Doyle, Francis J., III ;
Heller, Simon ;
Hovorka, Roman ;
Jia, Weiping ;
Jones, Tim ;
Kordonouri, Olga ;
Kovatchev, Boris ;
Kowalski, Aaron ;
Laffel, Lori ;
Maahs, David ;
Murphy, Helen R. ;
Norgaard, Kirsten ;
Parkin, Christopher G. ;
Renard, Eric ;
Saboo, Banshi ;
Scharf, Mauro ;
Tamborlane, William V. ;
Weinzimer, Stuart A. ;
Phillip, Moshe .
DIABETES CARE, 2017, 40 (12) :1631-1640
[9]  
Ekhlaspour Laya, 2017, J Diabetes Sci Technol, V11, P558, DOI 10.1177/1932296816672237
[10]   Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk [J].
Probstfield J.L. ;
Hirsch I.B. ;
Davis B.R. ;
Ahmann A. ;
Bergenstal R. ;
Gilbert M. ;
Kingry C. ;
Khakpour D. ;
Lai D. ;
Pressel S.L. ;
Branch K.R. ;
Riddle M. ;
O'Brien K.D. .
DIABETES CARE, 2016, 39 (06) :973-981